Clinical Trial

Neoadjuvant SNF Precision Therapy Phase III

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial designed to compare the efficacy and safety of neoadjuvant chemotherapy based on SNF classification with or without precision medicine agents in previously untreated patients with early-stage or locally advanced HR+/HER2- breast cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-30.
Status change: Not Yet Recruiting → Recruiting 2025-06-03
Trial Details
NCT Number NCT06913777
Lead Sponsor Fudan University
Conditions Neoadjuvant Therapy
Enrollment 404 participants
Start Date 2025-04-08
Primary Completion 2026-10-15 (estimated)
Study Completion 2027-04-15 (estimated)
Updated on ClinicalTrials.gov 2025-06-06